CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal

3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer

(2021) Barrie Peck et al.   CANCER RESEARCH

Trilaciclib: First Approval

(2021) Sohita Dhillon   DRUGS

Cell size homeostasis is maintained by CDK4-dependent activation of p38 MAPK

(2021) Ceryl Tan et al.   DEVELOPMENTAL CELL

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma

(2020) Beatriz Salvador-Barbero et al.   CANCER CELL

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

(2020) Mónica Álvarez-Fernández et al.   CANCER CELL

Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer

(2020) Marcus Ruscetti et al.   CELL

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

(2020) Franck Morschhauser et al.   HAEMATOLOGICA

The application and prospect of CDK4/6 inhibitors in malignant solid tumors

(2020) Qi Du et al.   Journal of Hematology & Oncology

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

(2020) Sara M Tolaney et al.   LANCET ONCOLOGY

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

(2020) Seth A. Wander et al.   Cancer Discovery

Topoisomerase IIα prevents ultrafine anaphase bridges by two mechanisms

(2020) Simon Gemble et al.   Open Biology

Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response

(2020) Sandrine Ragu et al.   Genes

Selective inhibition of CDK4/6: a safe and effective strategy for developing anticancer drugs

(2020) Kai Yuan et al.   Acta Pharmaceutica Sinica B

Role of p53 in the Regulation of Cellular Senescence

(2020) Mahmut Mijit et al.   Biomolecules

A Genetic Map of the Response to DNA Damage in Human Cells

(2020) Michele Olivieri et al.   CELL

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

(2020) Patrick J. Roberts et al.   MOLECULAR CANCER THERAPEUTICS

Senescence as a therapeutically relevant response to CDK4/6 inhibitors

(2020) Verena Wagner et al.   ONCOGENE

Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture

(2020) Eleanor Wendy Trotter et al.   Open Biology

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

(2020) Davey Daniel et al.   INTERNATIONAL JOURNAL OF CANCER

CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer

(2020) Ilenia Migliaccio et al.   CANCER TREATMENT REVIEWS

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary

(2019) Yibo Xue et al.   Nature Communications

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer

(2019) Yibo Xue et al.   Nature Communications

Exploiting DNA Replication Stress for Cancer Treatment

(2019) Tajinder Ubhi et al.   CANCER RESEARCH

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

(2019) Douglas Adkins et al.   LANCET ONCOLOGY

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

(2019) Seock-Ah Im et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

(2019) Antoinette R Tan et al.   LANCET ONCOLOGY

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

(2019) J M Weiss et al.   ANNALS OF ONCOLOGY

CDK4/6 inhibitors: taking the place of chemotherapy?

(2019) Azadeh Nasrazadani et al.   LANCET ONCOLOGY

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

(2019) Mario Giuliano et al.   LANCET ONCOLOGY

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

(2018) Mary E. Klein et al.   CANCER CELL

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib

(2018) Teemu P Miettinen et al.   EMBO JOURNAL

BEYOND THE CELL CYCLE: ENHANCING THE IMMUNE SURVEILLANCE OF TUMORS VIA CDK4/6 INHIBITION

(2018) Andrea C. Chaikovsky et al.   MOLECULAR CANCER RESEARCH

E-cadherin in contact inhibition and cancer

(2018) Alisha M. Mendonsa et al.   ONCOGENE

Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place

(2018) Panagiotis Kotsantis et al.   Cancer Discovery

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

(2018) David A. Schaer et al.   Cell Reports

An intrinsic S/G2 checkpoint enforced by ATR

(2018) Joshua C. Saldivar et al.   SCIENCE

CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest

(2018) Shom Goel et al.   TRENDS IN CELL BIOLOGY

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

(2018) Livnat Jerby-Arnon et al.   CELL

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

(2018) Marcus Ruscetti et al.   SCIENCE

Absence of RNase H2 triggers generation of immunogenic micronuclei removed by autophagy

(2017) Kareen Bartsch et al.   HUMAN MOLECULAR GENETICS

DNA damage-induced immune response: Micronuclei provide key platform

(2017) Nelson O. Gekara   JOURNAL OF CELL BIOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

cGAS surveillance of micronuclei links genome instability to innate immunity

(2017) Karen J. Mackenzie et al.   NATURE

Mitotic progression following DNA damage enables pattern recognition within micronuclei

(2017) Shane M. Harding et al.   NATURE

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

(2017) Shenghui He et al.   Science Translational Medicine

ATRX is a regulator of therapy induced senescence in human cells

(2017) Marta Kovatcheva et al.   Nature Communications

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers

(2017) Smruthi Vijayaraghavan et al.   Nature Communications

DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression

(2017) Alexis R. Barr et al.   Nature Communications

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines

(2017) Marion A.A. Libouban et al.   Oncotarget

Endogenous Replication Stress in Mother Cells Leads to Quiescence of Daughter Cells

(2017) Mansi Arora et al.   Cell Reports

Rapid DNA replication origin licensing protects stem cell pluripotency

(2017) Jacob Peter Matson et al.   eLife

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6

(2016) A. Yoshida et al.   CANCER RESEARCH

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Targeting the RB-E2F pathway in breast cancer

(2016) J Johnson et al.   ONCOGENE

Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells

(2016) Alberto Moreno et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New Insights into the Mechanism of DNA Duplication by the Eukaryotic Replisome

(2016) Luca Pellegrini et al.   TRENDS IN BIOCHEMICAL SCIENCES

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Progress with palbociclib in breast cancer: latest evidence and clinical considerations

(2016) Andrea Rocca et al.   Therapeutic Advances in Medical Oncology

DNA Replication Stress as a Hallmark of Cancer

(2015) Morgane Macheret et al.   Annual Review of Pathology-Mechanisms of Disease

Senescence from G2 arrest, revisited

(2015) Véronique Gire et al.   CELL CYCLE

TopBP1 is required at mitosis to reduce transmission of DNA damage to G1 daughter cells

(2015) Rune Troelsgaard Pedersen et al.   JOURNAL OF CELL BIOLOGY

Replication stress activates DNA repair synthesis in mitosis

(2015) Sheroy Minocherhomji et al.   NATURE

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

PICH promotes sister chromatid disjunction and co-operates with topoisomerase II in mitosis

(2015) Christian F. Nielsen et al.   Nature Communications

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

(2015) Marta Kovatcheva et al.   Oncotarget

Transient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence

(2014) Lenno Krenning et al.   MOLECULAR CELL

Necessary and Sufficient Role for a Mitosis Skip in Senescence Induction

(2014) Yoshikazu Johmura et al.   MOLECULAR CELL

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

Improved Genome Editing in Human Cell Lines Using the CRISPR Method

(2014) Ivan M. Munoz et al.   PLoS One

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion

(2013) Olga V. Leontieva et al.   CELL CYCLE

A complex secretory program orchestrated by the inflammasome controls paracrine senescence

(2013) Juan Carlos Acosta et al.   NATURE CELL BIOLOGY

Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer

(2012) D Maglic et al.   ONCOGENE

A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

(2011) Lars Anders et al.   CANCER CELL

Replication stress induces 53BP1-containing OPT domains in G1 cells

(2011) Jeanine A. Harrigan et al.   JOURNAL OF CELL BIOLOGY

Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment

(2011) Jürgen Cox et al.   JOURNAL OF PROTEOME RESEARCH

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development

(2011) Tae-Won Kang et al.   NATURE

53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress

(2011) Claudia Lukas et al.   NATURE CELL BIOLOGY

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

(2010) W. R. Wiedemeyer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Senescence of Activated Stellate Cells Limits Liver Fibrosis

(2008) Valery Krizhanovsky et al.   CELL

Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression

(2008) Asako Sakaue-Sawano et al.   CELL

MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification

(2008) Jürgen Cox et al.   NATURE BIOTECHNOLOGY

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

(2008) F. Di Nicolantonio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication

(2008) Arkaitz Ibarra et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA